University of California, Davis: Human Papillomavirus Cancer Free (UCD: HPV Cancer Free)

这份K01奖项的重新提交概述了一个密集的五年研究职业发展计划 专注于多层次的行为干预和传播与实施科学研究 增加和维持人类乳头瘤病毒(HPV)疫苗的接种量。支持候选人的职业生涯 研究目标是由行为干预研究专家组成的指导团队，高级 生物统计学方法、传播和实施科学以及临床专家小组。 完成候选人的培训计划和研究研究将为候选人提供经验， 成为领先的独立调查员所需的技能、知识、指导和试点数据 开发、实施和评估多层次行为干预措施，以减轻中国的癌症负担 种族/少数民族群体，首先是提高HPV疫苗接种率。 HPV疫苗是公共卫生的一项重大突破，是最佳的初级预防策略 对抗人乳头瘤病毒相关癌症。HPV疫苗的广泛使用有望减少癌症 所有种族/民族的负担，因为有色人种人口不成比例地受到HPV- 相关癌症。尽管疾控中心的建议和全面接种疫苗对公共健康的影响 在覆盖范围内，青少年中的HPV疫苗接种率仍远低于2030年健康人口80%的目标。 全国免疫调查报告称，2019年，13-17岁的美国青少年中只有54.2%的人 与这部系列剧相约。初步数据和文献回顾表明，多水平干预措施 解决至少两个层面的影响，显示出增加HPV疫苗接种率的希望。这样做的目的是 建议是开发、实施和评估多层次(家长、初级保健团队和诊所)干预措施 旨在将青少年HPV疫苗接种率提高到2030年健康人口接种率80%的目标 采用平行组整群随机试验设计。这项研究将评估多个水平的有效性 提高基层医疗机构9~17岁人群HPV接种率的干预措施 并将确定广泛传播和实施的障碍和促进者。这将会实现的 通过以下目标：1)细化和最终确定家长、初级保健团队和诊所ML干预，以 提高初级保健青少年患者对HPV疫苗系列的接种率和完成率 2)开展和评估ML干预措施的有效性和可持续性。这个 拟议的研究具有重要意义，因为它将为HPV疫苗多级接种这一新兴领域做出贡献 干预研究并满足对更科学、更严格、基于证据的干预的需求 这是可以大规模传播和实施的。成功采用广泛使用的HPV疫苗 覆盖计划将减少HPV相关癌症的种族/民族差异，方法是确保 这一代美国人不会经历由于HPV相关癌症而导致的不必要的死亡。

This K01 award resubmission outlines an intensive five-year research career development program focused on multilevel behavioral intervention and dissemination and implementation science research to increase and sustain uptake of the human papillomavirus (HPV) vaccine. Supporting the candidate's career and research goals is a mentoring team comprised of experts in behavioral intervention research, advanced biostatistics methods, and dissemination and implementation science as well as a clinical expert panel. Completion of the candidate's training plan and research study will provide the candidate with the experience, skills, knowledge, mentoring and pilot data needed to become a leading independent investigator in developing, implementing and evaluating multilevel behavioral interventions to reduce the burden of cancer in racial/ethnic minority groups, starting with increasing HPV vaccination rates. The HPV vaccine is a major public health breakthrough and is the optimal primary prevention strategy against HPV-associated cancers. Widespread use of the HPV vaccine is expected to reduce the cancer burden across all racial/ethnic group, as populations of color are disproportionately affected by HPV- associated cancers. Despite CDC recommendations and the public health implications of full vaccination coverage, HPV vaccine uptake among adolescents remains well below the Healthy People 2030 goal of 80%. The National Immunization Survey reported that in 2019, only 54.2% of U.S. adolescents aged 13-17 were up to date with the series. Preliminary data and a review of the literature suggest multilevel interventions that address at least two levels influence show promise in increasing HPV vaccine uptake. The objective of this proposal is to develop, implement and evaluate a multilevel (parent, primary care team, and clinic) intervention aimed at raising adolescent HPV vaccination rates to the Healthy People 2030 goal of 80% for boys and girls using a parallel group cluster randomized trial design. This study will assess the effectiveness of the multilevel intervention on increasing the rates of HPV vaccination among patients aged 9-17 of a primary care network and will identify barriers and facilitators for broad dissemination and implementation. This will be accomplished through the following aims: 1) Refine and finalize a parent, primary care team and clinic ML intervention to increase uptake and completion of the HPV vaccine series among adolescent patients of a primary care network; and 2) Conduct and evaluate the effectiveness and sustainability of the ML intervention. The proposed research is significant because it will contribute to the emerging field of HPV vaccination multilevel intervention research and addresses the need for more scientifically rigorous, evidence-based interventions that can be disseminated and implemented on a large scale. Successful adoption of widespread HPV vaccine coverage programs will reduce racial/ethnic disparities in HPV-associated cancer by ensuring that the next generation of Americans do not experience unnecessary deaths due to HPV-related cancers.